aclidinium vs umeclidinium/vilanterol
Side-by-side comparison of aclidinium and umeclidinium/vilanterol. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
Tudorza Pressair
Anoro Ellipta
No summary available.
Anoro Ellipta is a combination medicine used long-term to help people with COPD breathe better. It contains two medicines that open airways.
Information not available.
Anoro Ellipta is used to treat chronic obstructive pulmonary disease (COPD). COPD is a long-term lung disease that makes it hard to breathe. This medicine helps to open the airways in your lungs so you can breathe easier. It is not for sudden breathing problems.
Information not available.
Anoro Ellipta contains two medicines, umeclidinium and vilanterol. Umeclidinium is an anticholinergic that relaxes the muscles around your airways. Vilanterol is a LABA that also relaxes airway muscles. Together, they help to keep your airways open.
- • Upper respiratory infection
- • Headache
- • Back pain
- • Sore throat
- • Sinus infection
- • Lower respiratory infection
- • Constipation
- • Diarrhea
- Difficulty breathing 1,869
- Inhaler not working correctly 1,281
- Skipped a dose of medicine 1,017
- Asthma 814
- Chronic obstructive pulmonary disease (COPD) 764
- Shortness of breath 1,352
- Cough 701
- Asthma 604
- Using the inhaler incorrectly 520
- Pneumonia 509
No specific warnings noted.
LABA medicines like vilanterol, when used alone for asthma, can increase the risk of serious asthma problems, including death. Anoro Ellipta is not for asthma. Do not use Anoro Ellipta if you are allergic to milk proteins or any of the ingredients in Anoro Ellipta.
No pregnancy information available.
There is not enough information about using Anoro Ellipta during pregnancy to know if it is safe. Talk to your doctor if you are pregnant or plan to become pregnant. It is not known if Anoro Ellipta passes into breast milk.
Also Compare, Nearby Drugs
Compare aclidinium with
Compare umeclidinium/vilanterol with
How to Read This aclidinium vs umeclidinium/vilanterol Comparison
aclidinium is classified in the Long-Acting Muscarinic Antagonist (LAMA) drug class, while umeclidinium/vilanterol sits within the LAMA / LABA Combination class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aclidinium has 5,745 submissions while umeclidinium/vilanterol has 3,686. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. No direct interaction between these two drugs is listed in our FDA-derived dataset, though co-prescription still warrants pharmacist review. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot substitute for clinical judgment. Effectiveness, tolerability, drug-drug interactions with your other medications, kidney and liver function, pregnancy status, insurance formulary, and price all feed into a decision that only a licensed prescriber can make responsibly. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This page is for educational purposes only, is not medical advice, and should not be used to self-switch between aclidinium and umeclidinium/vilanterol - always consult your physician or pharmacist first.
Important: This comparison is for informational purposes only. Drug effects vary between individuals. Always consult your doctor or pharmacist for personalized medical advice.